FR2899111B1 - Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament. - Google Patents

Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament.

Info

Publication number
FR2899111B1
FR2899111B1 FR0602802A FR0602802A FR2899111B1 FR 2899111 B1 FR2899111 B1 FR 2899111B1 FR 0602802 A FR0602802 A FR 0602802A FR 0602802 A FR0602802 A FR 0602802A FR 2899111 B1 FR2899111 B1 FR 2899111B1
Authority
FR
France
Prior art keywords
concentrate
medicinal product
specific immunoglobulins
chikungunya
chikungunya specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0602802A
Other languages
English (en)
Other versions
FR2899111A1 (fr
Inventor
Roland Schmitthaeusler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0602802A priority Critical patent/FR2899111B1/fr
Application filed by LFB SA filed Critical LFB SA
Priority to EP07731239A priority patent/EP2004233A1/fr
Priority to CNA2007800111587A priority patent/CN101410138A/zh
Priority to CA002647506A priority patent/CA2647506A1/fr
Priority to KR1020087025548A priority patent/KR20080108556A/ko
Priority to PCT/FR2007/000561 priority patent/WO2007118987A1/fr
Priority to US11/912,439 priority patent/US20080219969A1/en
Priority to JP2009502155A priority patent/JP2009531401A/ja
Priority to AU2007239415A priority patent/AU2007239415A1/en
Priority to BRPI0709448-5A priority patent/BRPI0709448A2/pt
Publication of FR2899111A1 publication Critical patent/FR2899111A1/fr
Priority to IL193819A priority patent/IL193819A0/en
Application granted granted Critical
Publication of FR2899111B1 publication Critical patent/FR2899111B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un nouveau médicament destiné au traitement du chikungunya, à savoir un concentré d'immunoglobulines spécifiques du chikungunya ainsi que son procédé de préparation.
FR0602802A 2006-03-31 2006-03-31 Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament. Expired - Fee Related FR2899111B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR0602802A FR2899111B1 (fr) 2006-03-31 2006-03-31 Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament.
AU2007239415A AU2007239415A1 (en) 2006-03-31 2007-04-02 Concentrate of chikungunya-specific immunoglobulins as medicine
CA002647506A CA2647506A1 (fr) 2006-03-31 2007-04-02 Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament
KR1020087025548A KR20080108556A (ko) 2006-03-31 2007-04-02 약물로 작용하는 치군군야-특이적 면역글로블린 농축액
PCT/FR2007/000561 WO2007118987A1 (fr) 2006-03-31 2007-04-02 Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament
US11/912,439 US20080219969A1 (en) 2006-03-31 2007-04-02 Concentrate of Chikungunya-Specific Immunoglobulins as a Medicinal Product
EP07731239A EP2004233A1 (fr) 2006-03-31 2007-04-02 Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament
CNA2007800111587A CN101410138A (zh) 2006-03-31 2007-04-02 作为药用产品的对切昆贡亚热特异的免疫球蛋白的浓缩物
BRPI0709448-5A BRPI0709448A2 (pt) 2006-03-31 2007-04-02 concentrado de imunoglobulinas especìficas de chikungunya como um produto medicinal
JP2009502155A JP2009531401A (ja) 2006-03-31 2007-04-02 医薬品としてのチクングニヤ特異性免疫グロブリンの濃縮物、濃縮物の利用及び濃縮物を調整する方法
IL193819A IL193819A0 (en) 2006-03-31 2008-09-01 Concentrate of chikungunya-specific immunoglobulins as medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0602802A FR2899111B1 (fr) 2006-03-31 2006-03-31 Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament.

Publications (2)

Publication Number Publication Date
FR2899111A1 FR2899111A1 (fr) 2007-10-05
FR2899111B1 true FR2899111B1 (fr) 2010-09-03

Family

ID=37433721

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0602802A Expired - Fee Related FR2899111B1 (fr) 2006-03-31 2006-03-31 Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament.

Country Status (11)

Country Link
US (1) US20080219969A1 (fr)
EP (1) EP2004233A1 (fr)
JP (1) JP2009531401A (fr)
KR (1) KR20080108556A (fr)
CN (1) CN101410138A (fr)
AU (1) AU2007239415A1 (fr)
BR (1) BRPI0709448A2 (fr)
CA (1) CA2647506A1 (fr)
FR (1) FR2899111B1 (fr)
IL (1) IL193819A0 (fr)
WO (1) WO2007118987A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9441032B2 (en) 2010-04-07 2016-09-13 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374816B1 (fr) * 2010-04-07 2016-09-28 Agency For Science, Technology And Research Molécules liant le virus du Chikungunya et leurs utilisations
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814433A (en) * 1987-09-16 1989-03-21 Miles Inc. Method for obtaining a papain-free antibody fragment preparation
JPH06256215A (ja) * 1993-03-09 1994-09-13 Fuji Photo Film Co Ltd 多種特異性Ｆ（ａｂ’）３の作製方法
JPH1060000A (ja) * 1996-08-22 1998-03-03 Kanto Chem Co Inc 抗体の精製方法
JPH1059999A (ja) * 1996-08-22 1998-03-03 Kanto Chem Co Inc 抗体の分離精製法
EP0835880A1 (fr) * 1996-10-14 1998-04-15 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Procédé de préparation d'un médicament contenant de l'IgM administrable par voie intraveineuse
US5886154A (en) * 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
DK2270044T3 (en) * 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
EP1341788B1 (fr) * 2000-12-15 2005-08-10 Glaxo Group Limited Pyrazolopyridines
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
PT1946776T (pt) * 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
FR2899112B1 (fr) * 2006-03-31 2010-09-03 Lab Francais Du Fractionnement Concentre d'immunoglobulines et de fragments f (ab)'2 et/ou fab specifiques d'un arbovirus en tant que medicament.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9441032B2 (en) 2010-04-07 2016-09-13 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
US9738704B2 (en) 2010-04-07 2017-08-22 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof

Also Published As

Publication number Publication date
EP2004233A1 (fr) 2008-12-24
WO2007118987A1 (fr) 2007-10-25
FR2899111A1 (fr) 2007-10-05
IL193819A0 (en) 2011-08-01
CA2647506A1 (fr) 2007-10-25
BRPI0709448A2 (pt) 2011-07-12
KR20080108556A (ko) 2008-12-15
CN101410138A (zh) 2009-04-15
US20080219969A1 (en) 2008-09-11
JP2009531401A (ja) 2009-09-03
AU2007239415A1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
MA42230B1 (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA30514B1 (fr) Nouveaux composes.
MA33987B1 (fr) Bloqueurs de canaux sodiques sensibles au potentiel
EP2666471A4 (fr) Composition pharmaceutique pour la traitement de la rate et de l'estomac, ainsi que procédé de préparation de cette composition
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
ES2144623T3 (es) Heterociclos diaril biciclicos como inhibidores de la ciclooxigenasa-2.
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
MA33924B1 (fr) Dérivés de 2-arylimidazole en tant qu'inhibiteurs de l'enzyme pde10a
BR112015003658A2 (pt) formulações de lipossomas
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
MA35674B1 (fr) Derives de chromone, leur procede de preparation et leurs applications therapeutiques
DK1670903T3 (da) Behandling af neurodegenerative sygdomme
MA37742A1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA33218B1 (fr) Applications therapeutiques de derives de quinazolinedione
MA30630B1 (fr) Nouveaux derives chromenes ou thiochromenes carboxamides, leur procede de preparation et leurs applications en therapeutique.
PT1778837E (pt) Tratamento de doenças neurodegenerativas por utilização de inibidores de scd4
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
EA201100884A1 (ru) Моноклональные антитела анти-rhd
GT200500028A (es) Oxadiazolonas, procedimientos para su preparacion y su uso como productos farmaceuticos.
WO2018193090A3 (fr) Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci
MX2014014066A (es) Compuestos de cromano.
BRPI0416188A (pt) formulações de medicamentos que contêm aromatizante, com propriedades farmacêuticas aperfeiçoadas
FR2899111B1 (fr) Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament.
EP2328877A4 (fr) Composés de 1,4-benzoxazine, et dérivés de ceux-ci en tant que médicaments thérapeutiques pour le traitement de troubles neurodégénératifs

Legal Events

Date Code Title Description
CL Concession to grant licences
ST Notification of lapse

Effective date: 20141128